Impact of Epilepsy

The physical, emotional, and cognitive consequences of seizures can build over time–affecting patients’ daily lives.

The physical, emotional, and cognitive consequences of seizures can build over time–affecting patients’ daily lives.

Patients have a lot to lose with just 1 seizure

When seizures remain uncontrolled, patients are1*:

~6x

more likely
to have
depression

4.5x

more likely to
be prevented
from driving

3x

more likely to
experience
limitations in
employment

2x

more likely
to have
limits in
education

*Based on data that compared patients who had ≥1 seizure in the past 5 years with those who experienced no seizures in the past 5 years.

Epilepsy is associated with various comorbidities5

Patients with uncontrolled seizures have an increased risk of comorbidities.†‡

Heart

Cardiac and Metabolic

1.5-2x

more likely to have atrial fibrillation (AFib)

Neuro-psychiatric

Neuro-psychiatric

3x

more likely to have non-epileptic seizures

Neurologic

Neurologic

1.5-2x

more likely to have
brain trauma

1.5-2x

more likely to develop dementia/Alzheimer’s

1.5-2x

more likely to have a stroke

†Incidence of comorbidities in patients with uncontrolled vs controlled epilepsy following initiation of first-line and third-line anti-seizure medication (ASM).
‡Uncontrolled epilepsy was defined by ≥1 of the following events: seizure-related inpatient visit, seizure-related emergency room visit, or new ASM line of therapy initiation.
Lightbulb

Patients with seizures have an increased risk of SUDEP2§

UP TO

9.3

deaths per 1000 person-years in patients with refractory epilepsy3

30x

Secondary generalized tonic-clonic seizures put patients at a 30x higher risk for SUDEP compared with other seizure types4

§Based on data that compared patients who had ≥1 seizure in the previous year with those who had zero seizures in the previous year.

SUDEP=sudden unexpected death in epilepsy.

Hear expert recommendations on the SUDEP patient conversation 

Selim Benbadis, MD, speaks to the importance of overcoming complacency in drug-resistant patients and why discussing the risk of SUDEP with patients and caregivers is a critical conversation to have.

Lightning bolt

Powerful efficacy

XCOPRI provides proven seizure reduction and a chance for zero seizures

Explore XCOPRI efficacy
10 plus years

10+ years of clinical trial and real-world experience

Well-studied safety, with over 220,000 patients treated worldwide* and long-term retention rates

Review safety profile
*Worldwide new-to-brand cenobamate prescriptions as of June 2025. Source: IQVIA.
References: 1. Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764-771. 2. Nilsson L, Farahmand BY, Persson P-G, Thiblin I, Tomson T. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet. 1999;353(9156):888-893. 3. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075-1088. 4. Shlobin NA, Thijs RD, Benditt DG, Zeppenfeld K, Sander JW. Sudden death in epilepsy: the overlap between cardiac and neurological factors. Brain Commun. 2024;6(5):fcae309. 5. Faught E, Kerr WT, Stern S, Wade CT, Klatte E. Increased incidence of comorbidities in patients with uncontrolled epilepsy. Poster presented at: American Epilepsy Society Annual Meeting; December 1-3, 2023; Orlando, FL. 6. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279-286. 7. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3)(suppl):1-14. 8. Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142(2):91-107. 9. Keppra [package insert]. Smyrna, GA: UCB, Inc; 2024. 10. Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2025. 11. Vimpat [package insert]. Smyrna, GA: UCB, Inc; 2023. 12. Sabril [package insert]. Deerfield, IL: Lundbeck; 2021. 13. Fycompa [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2023. 14. Aptiom [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2019. 15. Potiga [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2024.
Expand

INDICATION

XCOPRI is indicated for the
treatment of partial-onset
seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI is contraindicated in patients with hypersensitivity to cenobamate or any of the ingredients in the product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

Collapse IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in patients with hypersensitivity to cenobamate or any of the ingredients in the product. 

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Liver Injury: Clinically significant liver injury has occurred in patients taking XCOPRI. Obtain serum transaminases (ALT and AST) and total bilirubin, if not recently available (i.e., within 3 months) before initiating XCOPRI, and during treatment if clinically indicated. Monitor patients for signs and symptoms of any hepatic injury during treatment. Discontinue XCOPRI in patients with evidence of liver injury in the absence of an alternative etiology.

Neurological Adverse Reactions: XCOPRI can cause dose-dependent increases in the neurologic adverse reactions including dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI.
  • When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI is not recommended in end-stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI is not recommended in patients with severe hepatic impairment.

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see full Prescribing Information.